Wound Healing Potential of Human Umbilical Cord Blood and Placental Membrane Derived Products

Additional Funding Sources

The project described was supported by Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant Nos. P20GM103408 and P20GM109095. We also acknowledge support from The Biomolecular Research Center at Boise State with funding from the National Science Foundation, Grant Nos. 0619793 and 0923535, the MJ Murdock Charitable Trust, and the Idaho State Board of Education.

Presentation Date

7-2018

Abstract

Wound Healing is a complex process involving hemostasis, inflammation, proliferation and maturation stages. Treatment of chronic wound is a significant challenge for clinicians and warrant urgent need for alternate therapies. Stem cell-based therapy is one of the techniques employed for wound healing but, a successful transplantation is depended upon homing, engraftment and repopulation of stem cells. Due to involvement of multiple and complex pathways the success of transplantation can be hindered. Another approach is to use the cell signaling molecules and growth factors of stem cells to regenerate the damaged site by recruiting host’s stem cells. Cellular allograft derived from umbilical cord blood and dehydrated amniotic membranes are an enriched source of cytokines and growth factors needed for activation of mesenchymal stromal cells to participate in wound healing process. Using bone marrow derived mesenchymal stromal cells as model system, we assessed the regenerative potential of BioBurst Fluid (an umbilical cord blood derived product) and Burst Binate Patch (an amniotic tissue derived product) using cellular proliferation, migration, osteogenesis and angiogenesis assays. Our data shows that the cytokines and growth factors associated with these products support biological processes involved in bone healing.

Comments

Th15

This document is currently not available here.

Share

COinS
 

Wound Healing Potential of Human Umbilical Cord Blood and Placental Membrane Derived Products

Wound Healing is a complex process involving hemostasis, inflammation, proliferation and maturation stages. Treatment of chronic wound is a significant challenge for clinicians and warrant urgent need for alternate therapies. Stem cell-based therapy is one of the techniques employed for wound healing but, a successful transplantation is depended upon homing, engraftment and repopulation of stem cells. Due to involvement of multiple and complex pathways the success of transplantation can be hindered. Another approach is to use the cell signaling molecules and growth factors of stem cells to regenerate the damaged site by recruiting host’s stem cells. Cellular allograft derived from umbilical cord blood and dehydrated amniotic membranes are an enriched source of cytokines and growth factors needed for activation of mesenchymal stromal cells to participate in wound healing process. Using bone marrow derived mesenchymal stromal cells as model system, we assessed the regenerative potential of BioBurst Fluid (an umbilical cord blood derived product) and Burst Binate Patch (an amniotic tissue derived product) using cellular proliferation, migration, osteogenesis and angiogenesis assays. Our data shows that the cytokines and growth factors associated with these products support biological processes involved in bone healing.